EGCG adjuvant chemotherapy: Current status and future perspectives

The resistance of Cancer cells to chemotherapeutic drugs greatly reduces the therapeutic effect in Cancer patients, and the toxic side effects caused by chemotherapy also seriously affect the quality of life of patients. The combination of epigallocatechin-3-gallate (EGCG), the main active ingredient in tea, with cisplatin, 5-FU, doxorubicin and paclitaxel enhances their sensitizing effect on tumors and combats the drug resistance of Cancer cells. These effects seem to be mediated by a variety of mechanisms, including combating drug resistance mediated by Cancer Stem Cells, enhancing drug sensitivity, inducing cell cycle arrest and Apoptosis, and blocking angiogenesis. In addition, EGCG can suppress a series of adverse effects caused by chemotherapy, such as gastrointestinal disorders, nephrotoxicity and cardiotoxicity, through its anti-inflammatory and antioxidant effects and improve the quality of life of patients. However, the low bioavailability and off-target effects of EGCG and its reactivity with some chemotherapeutic agents limit its clinical application. The nanomodification of EGCG and chemotherapeutic drugs not only enhances the antitumor activity but also prolongs the survival time of tumor-bearing mice, and has the advantage of low toxicity. Therefore, this review aims to discuss the current status and challenges regarding the use of EGCG in combination with chemotherapy drugs in the treatment of Cancer. In general, EGCG is a promising Adjuvant for chemotherapy.

Cancer therapy; Chemotherapy; Epigallocatechin-3-gallate; Nanomaterials; Side effects.